William D. McClellan Jr. - 07 Jun 2023 Form 4 Insider Report for REATA PHARMACEUTICALS INC (RETA)

Role
Director
Signature
/s/ Tracy Herson, attorney-in-fact
Issuer symbol
RETA
Transactions as of
07 Jun 2023
Transactions value $
$177,321
Form type
4
Filing time
09 Jun 2023, 16:20:37
Previous filing
04 Apr 2023
Next filing
01 Aug 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RETA Class A common stock Award $9.92K +106 +2.51% $93.61 4.34K 07 Jun 2023 Direct F1, F2
transaction RETA Class A common stock Award $157K +1.68K +38.8% $93.61 6.02K 07 Jun 2023 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction RETA Stock Option (right-to-buy) Award $9.95K +135 $73.68 135 07 Jun 2023 Class A common stock 135 $93.61 Direct F3, F4
transaction RETA Stock Option (right-to-buy) Award $0 +2.14K $0.00 2.14K 07 Jun 2023 Class A common stock 2.14K $93.61 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares represent Restricted Stock Units (RSUs), which vest on June 5, 2024, subject to continued service through the vesting date.
F2 These RSUs were issued to the reporting person pursuant to the Reata Non-Employee Director Compensation Policy in lieu of future director fees of $9,923.
F3 The option vests in 4 equal installments on September 7, 2023, December 7, 2023, March 7, 2024, and June 5, 2024, subject to continued service through each vesting date.
F4 This option was issued to the reporting person pursuant to the Reata Non-Employee Director Compensation Policy in lieu of future director fees of $9,947.